Central African Republic vs Germany: Protecting minority investors: Ease of shareholder suits index (0-10)
Central African Republic
50
in 2019
Germany
50
in 2019
Central African Republic rank
128th
Germany rank
128th
Protecting minority investors: Ease of shareholder suits index (0-10) over time
- Central African Republic
- Germany
How they compare
Central African Republic currently reports 50 against 50 in Germany, a difference of 0.
Across all 7 years both countries report, Germany has been ahead every year.
Central African Republic ranks 128th and Germany ranks 128th of 191 countries.
Germany has averaged higher in every one of the 1 decades both report.
Frequently asked questions
- Which has higher protecting minority investors: ease of shareholder suits index (0-10), Central African Republic or Germany?
- Central African Republic, at 50 against 50 in Germany as of 2019.
- What is the difference in protecting minority investors: ease of shareholder suits index (0-10) between Central African Republic and Germany?
- 0, with Central African Republic ahead.
- How many years of comparable data are there for Central African Republic and Germany?
- 7 years are reported by both, from 2013 to 2019.
- How do Central African Republic and Germany rank globally for protecting minority investors: ease of shareholder suits index (0-10)?
- Central African Republic ranks 128th and Germany ranks 128th of 191 countries.
- Where does this data come from?
- The World Bank, published as Protecting minority investors: Ease of shareholder suits index (0-10) (DB15-20 methodology) - Score. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The score for ease of shareholder suits index benchmarks economies with respect to the regulatory best practice on the indicator. The score is indicated on a scale from 0 to 100, where 0 represents the worst regulatory performance and 100 the best regulatory performance, and is computed based on the methodology in the DB15-20 studies.